COMMUNIQUÉS West-GlobeNewswire

CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
09/03/2026
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 In the fourth paragraph, we are replacing milligrams with micrograms . The corrected press release follows. CARMEL, Ind., March 09, [...]
Transactions in Connection with Share Buy-back Program
09/03/2026
Company Announcement COPENHAGEN, Denmark; March 9, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum [...]
EssilorLuxottica: Disclosure of transactions in own shares
09/03/2026
Disclosure of transactions in own shares Paris, France (March 9, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that from [...]
GENFIT reçoit la désignation Orphan Drug de la FDA pour NTZ dans le traitement de l’ACLF
09/03/2026
La FDA accorde la désignation Orphan Drug (ODD) à NTZ dans l'ACLF, syndrome grave pour lequel il n'existe aucun traitement approuvé NTZ est développé dans l'ACLF via sa nouvelle formulation G1090N, conçue pour optimiser [...]
Radiant Health Centers Announces Honorees for 40th Annual Gala Celebrating Four Decades of Compassionate Care
09/03/2026
Jai Rodriguez and Harper Steele Headline Evening Honoring Cultural Impact, Legacy Leadership, and Community Hope Irvine, CA, March 09, 2026 (GLOBE NEWSWIRE) -- Radiant Health Centers , Orange County’s largest provider [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
09/03/2026
Déclaration de transactions sur actions propres Paris, France (9 mars 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que du 2 mars 2026 au 4 [...]
Hyperion DeFi Announces Private Lending Pool Built by HyperLend
09/03/2026
Unlocks Cost-Optimized On-Chain Credit Access, Additional Ecosystem Rewards, and Expanded Revenue Opportunities in Institutional Credit LAGUNA HILLS, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. ( [...]
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
09/03/2026
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry [...]
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
09/03/2026
Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucel Smital Shah appointed Chief Financial and Business Officer SOUTH [...]
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
09/03/2026
97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months 100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating [...]
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
09/03/2026
Dr. Robert Lenz brings over 20 years of experience in neuroscience drug development NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late- [...]
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
09/03/2026
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company [...]
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
09/03/2026
RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic [...]
Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders
09/03/2026
-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in mid-2026, with [...]
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
09/03/2026
BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
09/03/2026
CDI-988 is a direct-acting, oral antiviral being developed for norovirus Norovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No approved treatments or [...]
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
09/03/2026
Oak Ridge, TN, March 09, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that CEO and President Michael Feldschuh will participate in the [...]
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
09/03/2026
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
09/03/2026
TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to [...]

Pages